Martina Porter, MD, a Dermatologist at Beth Israel Deaconess Medical Center in Boston, MA, takes a deep dive into new four-year data on continuous treatment with secukinumab (Cosentyx, Novartis) in patients with hidradenitis suppurativa (HS) that was presented at the 10th annual Symposium on Hidradenitis Suppurativa Advances (SHSA) in Nashville, TN. Dr. Porter also discusses the changing treatment landscape for HS.
